Form 4 for BCRX BIOCRYST PHARMACEUTICALS INC
Accepted 2026-05-19 16:07:43 ET · period of report 2026-05-18 · accession 0000882796-26-000023 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-05-19 16:07 | 2026-05-18 | BCRX | McKee Amy E | Dir | S - Sale | $8.97 | -11.2K | 31.3K | -26% | -$100.3K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-05-18 | S | D | 11,180 | $8.97 | 31,252 | D | — | — | (F1) The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $8.96 to $8.985. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. |